Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study

被引:0
|
作者
Bitterman, Roni [1 ]
Awwad, Aya [2 ]
Darawsha, Basel [2 ]
Dallashi, Hajar [3 ]
Dishon-Benattar, Yael [1 ,4 ]
Pollack, Dina [5 ]
Paul, Mical [1 ]
机构
[1] Rambam Hlth care Campus, Div Infect Dis, Haifa, Israel
[2] Technion Israeli Inst Technol, Fac Med, Haifa, Israel
[3] Rambam Hlth Care Campus, Internal Med B, Haifa, Israel
[4] Univ Haifa, Cheryl Spencer Dept Nursing, Haifa, Israel
[5] Rambam Hlth care Campus, Microbiol Lab, Haifa, Israel
关键词
COMMUNITY-ACQUIRED PNEUMONIA; PEDIATRIC-PATIENTS; INTEGRATED ANALYSIS; COMPLICATED SKIN; NON-INFERIORITY; PLUS AZTREONAM; RISK-FACTORS; DOUBLE-BLIND; MULTICENTER; FOSAMIL;
D O I
10.1093/jac/dkaf009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Vancomycin remains the treatment-of-choice in MRSA bacteraemia (MRSAB) despite significant limitations. Objective: To compare the effectiveness of ceftaroline and vancomycin monotherapy as the initial targeted therapy for MRSAB. Methods: We conducted a retrospective matched cohort study. Consecutive adult patients treated with ceftaroline in the years 2019-2021 were matched in a 1:2 ratio with patients who received vancomycin. Controls were matched for performance of trans-oesophageal echocardiography, Charlson comorbidity index and age. The primary outcome was a composite of treatment failure, defined as 90-day mortality or microbiological failure. Descriptive statistics were used to compare the ceftaroline and vancomycin-treated groups. Univariate and multivariable binary logistic regression models were created using ceftaroline treatment as the exposure variable. Results: Forty-five patients treated with ceftaroline for MRSAB were matched with 83 patients who received vancomycin. The groups were well balanced with regards to demographics and clinical characteristics. The primary outcome of treatment failure occurred at a similar rate in patients treated with ceftaroline or vancomycin (51.1%, 23/45% versus 57.8%, 48/83, respectively, P = 0.47). In the multivariable analysis, only age (aOR 1.06, 95% CI 1.01-1.1, P = 0.02) was associated with treatment failure. Acute kidney injury was more common among patients treated with ceftaroline (51.1%, 23/45% versus 18.1%, 15/83, P < 0.001). Conclusions: Ceftaroline was not associated with improved outcomes compared to vancomycin when given as initial treatment for MRSAB, however, it appears to be a viable alternative to vancomycin. Larger studies are needed to provide definitive results and to elucidate the risk of nephrotoxicity.
引用
收藏
页码:848 / 856
页数:9
相关论文
共 50 条
  • [31] Treatment of Methicillin-Resistant Staphylococcus aureus in Neonatal Mice: Lysostaphin Versus Vancomycin
    Placencia, Frank X.
    Kong, Lingkun
    Weisman, Leonard E.
    PEDIATRIC RESEARCH, 2009, 65 (04) : 420 - 424
  • [32] Linezolid Versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Keratitis in Rabbits
    Tas, Tekin
    Kucukbayrak, Abdulkadir
    Hakyemez, Ismail N.
    Mengeloglu, Firat Z.
    Simavli, Huseyin
    Ozyalvacli, Gulzade
    Erdurmus, Mesut
    CORNEA, 2013, 32 (07) : 1052 - 1057
  • [33] Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration &gt;1 mg/L: A Matched Cohort Study
    Murray, Kyle P.
    Zhao, Jing J.
    Davis, Susan L.
    Kullar, Ravina
    Kaye, Keith S.
    Lephart, Paul
    Rybak, Michael J.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) : 1562 - 1569
  • [34] Treatment of Methicillin-Resistant Staphylococcus aureus in Neonatal Mice: Lysostaphin Versus Vancomycin
    Frank X Placencia
    Lingkun Kong
    Leonard E Weisman
    Pediatric Research, 2009, 65 : 420 - 424
  • [35] Methicillin-resistant Staphylococcus aureus bacteraemia and epidural abscess in a neonate
    Stewart, Phoebe
    Khatami, Ameneh
    Loughran-Fowlds, Alison
    Isaacs, David
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2015, 51 (04) : 458 - 460
  • [36] Methicillin-resistant Staphylococcus aureus bacteraemia at a tertiary teaching hospital
    Cheong, I
    Samsudin, LM
    Law, GH
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1996, 50 (05): : 237 - 239
  • [37] Methicillin-resistant Staphylococcus aureus bacteraemia and mortality in a teaching hospital
    C. J. Beeston
    R. Gupta
    P. R. Chadwick
    R. J. Young
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28
  • [38] Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia
    Lewis, Paul O.
    Heil, Emily L.
    Covert, Kelly L.
    Cluck, David B.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (05) : 614 - 625
  • [39] Methicillin-resistant Staphylococcus aureus bacteraemia and mortality in a teaching hospital
    Beeston, C. J.
    Gupta, R.
    Chadwick, P. R.
    Young, R. J.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (06) : 585 - 590
  • [40] Ceftaroline plus Rifampin Versus Vancomycin plus Rifampin in the Treatment of Methicillin-Resistant Staphylococcus aureus Meningitis in an Experimental Rabbit Model
    Akdag, Damla
    Turhan, Tuncer
    Bolat, Elif
    Sanlidag-Isbilen, Gamze
    Tomruk, Canberk
    Isbilen, Furkan
    Uyanikgil, Yigit
    Aydemir, Sohret
    Yamazhan, Tansu
    Pullukcu, Husnu
    Arda, Bilgin
    Tasbakan, Meltem
    Gokkilic, Berke
    Kartal, Ekin
    Elik, Dilsah Baskol
    Sipahi, Hilal
    Ulusoy, Sercan
    Sipahi, Oguz Resat
    SURGICAL INFECTIONS, 2025,